Agios Pharmaceuticals Inc

NASDAQ:AGIO  
47.17
+1.37 (+2.99%)
Products

Agios Announces FDA Acceptance And Priority Review Of New Drug Application For Mitapivat For Treatment Of Adults With Pyruvate Kinase Deficiency

Published: 08/17/2021 21:01 GMT
Agios Pharmaceuticals Inc (AGIO) - Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults With Pyruvate Kinase Deficiency.
Agios Pharmaceuticals - NDA Was Granted Priority Review Designation & Has Been Given a PDUFA Action Date of Feb 17, 2022.